REG - AstraZeneca PLC - AstraZeneca to complete direct listing on NYSE

AstraZenecaAnnouncement

20/01/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260120:nRST4868Pa&default-theme=true

RNS Number : 4868P  AstraZeneca PLC  20 January 2026

20 January 2026

 

AstraZeneca to complete direct listing of ordinary shares and all US debt
securities on the New York Stock Exchange

 

Ticker symbol for ordinary shares will remain AZN

 

AstraZeneca PLC ("AstraZeneca") today provided notice of the voluntary
withdrawal from listing on The Nasdaq Stock Market LLC ("Nasdaq") of (i) its
American Depositary Shares (the "ADSs"), representing AstraZeneca's ordinary
shares of $0.25 each (the "Ordinary Shares") on a two-for-one basis and (ii)
debt securities issued by AstraZeneca or its wholly-owned subsidiary
AstraZeneca Finance LLC and guaranteed by AstraZeneca (the "Debt Securities").
As previously announced on 29 September 2025, AstraZeneca plans to complete a
direct listing of its Ordinary Shares and the Debt Securities on the New York
Stock Exchange (the "NYSE"), which will be effective after market close on 30
January 2026. The direct listing is a part of AstraZeneca's shareholder
approved plan to harmonise its share listing structure to deliver a global
listing for global investors in a global company. Following implementation of
the Harmonised Listing Structure, shareholders will be able to trade their
interests in the Ordinary Shares across the London Stock Exchange, Nasdaq
Stockholm and the NYSE.

 

The listing of the ADSs and the Debt Securities on Nasdaq is expected to cease
on 30 January 2026 and the Ordinary Shares and Debt Securities are expected to
commence trading on the NYSE from Monday, 2 February 2026. The Ordinary Shares
will continue to be listed under the ticker symbol "AZN".

 

Debt securities

For details on the Debt Securities, including outstanding US
dollar-denominated and US-listed debt securities please visit
https://www.astrazeneca.com/investor-relations/debt-investors.html.

 

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are
sold in more than 125 countries and used by millions of patients worldwide.
Please visit astrazeneca.com and follow the Company on social media
@AstraZeneca. The contents of AstraZeneca's website do not form part of this
document and no one should rely on such websites or the contents thereof in
reading this document.

 

Contacts

For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.

Matthew Bowden

Company Secretary

AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDUKUNRNBUAAAR



            Copyright 2019 Regulatory News Service, all rights reserved